CandlesenseCandlesense
News/Companies/REVB

REVB News

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

REVB

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team con

August 8, 2025Earnings
Read more →

Revelation Biosciences Announces Pricing Of $4M Public Offering Of Up To 14.56M Shares AT An Offering Price Of $1.10/Shr

REVB

May 29, 2025
Read more →

Revelation Biosciences Q1 EPS $(2.11) Beats $(5.96) Estimate

REVB

May 8, 2025
Read more →

Revelation Biosciences Says Gemini Priming Attenuates The Inflammatory Response In Human Peripheral Blood Mononuclear Cells Exposed To Clinically Relevant Promoter Molecules Of Inflammation

REVB

March 17, 2025
Read more →

Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $21.45 Price Valuation

REVB

March 7, 2025
Read more →

Revelation Biosciences Advances Gemini With First Patient Dosed In PRIME Phase 1b CKD Study

REVB

February 26, 2025
Read more →

Revelation Biosciences Advances PRIME Phase 1b Trial for Chronic Kidney Disease Treatment, Maintains Nasdaq Listing, Meets All Compliance Requirements

REVB

February 24, 2025
Read more →